✦ LIBER ✦

Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

✍ Scribed by Robert L Coleman; Linda R Duska; Pedro T Ramirez; John V Heymach; Aparna A Kamat; Susan C Modesitt; Kathleen M Schmeler; Revathy B Iyer; Michael E Garcia; Debbie L Miller; Edward F Jackson; Chaan S Ng; Vikas Kundra; Robert Jaffe; Anil K Sood

Book ID: 117785784
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 208 KB
Volume: 12
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70244-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Beyond tertiary cytoreduction in patient

Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

✍ K.K. Shih; D.S. Chi; R.R. Barakat; M.M. Leitao Jr. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Randomised phase II study of docetaxel p

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904

✍ Coleman, Robert L.; Moon, James; Sood, Anil K.; Hu, Wei; Delmore, James E.; Bone 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 887 KB

Phase II evaluation of topotecan and nav

Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer

✍ Thomas J. Herzog; Matthew A. Powell; Janet S. Rader; Randall K. Gibb; Lynne Lipp 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 424 KB

A phase II trial of weekly docetaxel in

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer

✍ Anna Berkenblit; Michael V. Seiden; Ursula A. Matulonis; Richard T. Penson; Caro 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Tertiary cytoreduction in patients with

Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: An updated series

✍ K.K. Shih; D.S. Chi; R.R. Barakat; M.M. Leitao Jr. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 203 KB

Phase II study of bevacizumab and pemetr

Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

✍ Hagemann, Andrea R.; Novetsky, Akiva P.; Zighelboim, Israel; Gao, Feng; Massad, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 264 KB